<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>PEG-MGF: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-peg-mgf</link>
    <atom:link href="https://greypeptides.com/changes/peg-mgf.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about PEG-MGF on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 30 Oct 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>Correction: Corrected: PEG-MGF</title>
      <link>https://greypeptides.com/corrections/#c-q1012-pegmgf-variant</link>
      <guid isPermaLink="false">greypeptides-changes-peg-mgf-corr-c-q1012-pegmgf-variant</guid>
      <pubDate>Fri, 30 Oct 2026 12:00:00 +0000</pubDate>
      <category>Correction</category>
      <description>MGF is the 24 C-terminal residues of the IGF-1Eb splice variant; no pharmacokinetic study of PEG-MGF exists, so no half-life is given.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA said it will hold a second committee meeting before the end of February 2027 on five more substances: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF. No date had been set as of November 2, 2026.</title>
      <link>https://greypeptides.com/regulatory/alerts/#pcac-second-meeting-planned</link>
      <guid isPermaLink="false">greypeptides-changes-peg-mgf-alert-pcac-second-meeting-planned</guid>
      <pubDate>Wed, 15 Apr 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Until that meeting and an FDA decision after it, none of the five can be compounded by a 503A pharmacy, except GHK-Cu for non-injectable use.</description>
    </item>
  </channel>
</rss>
